Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C
Author:
- 20 May 2010
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 31 (12) , 1251-1267
Abstract
Aliment Pharmacol Ther 31, 1251–1267Summary: Background For patients with chronic hepatitis C, attaining rapid virological response (RVR) is highly predictive of attaining SVR.Aim To consider the predictive value of RVR in terms of SVR and relapse.Methods Data were collected from published clinical trials to define the predictive value of RVR for SVR and evaluate the proposed continuum linking RVR to relapse.Results These data support a 24‐week regimen among genotype (G)1 patients who attain RVR with positive predictive values (PPVs) of 77.8% and 85.7% in patients with G1 infection treated for 24 and 48 weeks. Conversely, failure to attain RVR among G1 patients should not be viewed as a criterion for extending treatment duration beyond 48 weeks: negative predictive values (NPVs) were 60.9% and 52.7% in G1 patients without RVR treated for 48 and 72 weeks. Among G2/3 patients, RVR has a high PPV; however, the NPV varied with treatment duration indicating that a 24‐week treatment regimen is warranted in G2/3 patients who fail to attain RVR.Conclusions The present analysis confirms RVR as a strong predictor of SVR that can be used to tailor treatment duration, but which also should be appreciated in the context of treatment duration and regimen.Keywords
This publication has 30 references indexed in Scilit:
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trialHepatology, 2008
- Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis CClinical Infectious Diseases, 2008
- Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic responseHepatology, 2007
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisJournal of Hepatology, 2007
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C VirusThe Journal of Infectious Diseases, 2004